medicine-products/3-point-26reg-3b-polycentric-hinged-ulnar-deviation-splint-12181-1/;+health+history;+medical+history.html

Breaking Biology Technology:Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4 Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2 Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3 34th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 2 34th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 3

[0] Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer [0] Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A [0] Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. [0] 34th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research

Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2 For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3 Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2 VA Announces 2426 Million Construction Contract for Palo Alto 51841 1 Vein Removal Method Linked to Bypass Results 51837 1 Vein Removal Method Linked to Bypass Results 51837 2 Vein Removal Method Linked to Bypass Results 51837 3 Affordable Health Choices Act Is an Excellent Step Toward Health Care Reform 51832 1 Affordable Health Choices Act Is an Excellent Step Toward Health Care Reform 51832 2

[0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain [0] Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference